文献速递免疫规划

健康1岁日本儿童中麻腮风疫苗(JVC-001;麻疹AIK-C株、腮腺炎RIT4385株和风疹Takahashi株)的非劣效性与疫苗滴度确认研究

Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.
PubMed 文献 · Vaccine · 2025-02-06

两项3期多中心随机观察者盲法研究:J301比较单剂JVC-001与对照疫苗(麻疹-风疹疫苗+腮腺炎疫苗[Hoshino株])的免疫原性,J302比较不同滴度JVC-001的免疫原性与安全性。J301完成861人(JVC-001组429人,对照组432人),J302完成100人(低滴度组48人,高滴度组52人)。麻疹和风疹抗体滴度非劣效性成立,腮腺炎病毒基因型D抗体滴度非劣效性未确认;低滴度组与高滴度组血清阳性率相似;两项研究均无导致停药的事件或无菌性脑膜炎病例。

要点

  • 麻疹和风疹血清阳性率JVC-001组≥99.5%,非劣效性成立。
  • 腮腺炎病毒基因型D血清阳性率JVC-001组80.6% vs 对照组88.1%,非劣效性未确认。
  • 低滴度组与高滴度组血清阳性率相似;无导致停药事件或无菌性脑膜炎病例。

核心结论

  • 尽管JVC-001对现行获批疫苗在腮腺炎组分上未显示非劣效性,但提示有临床意义和一致的效力。
  • 疫苗滴度不影响免疫原性。
  • JVC-001预期较现行获批疫苗无菌性脑膜炎风险更低,且未出现新的安全性信号。

研究设计与样本

  • 两项3期多中心随机观察者盲法研究,纳入健康日本1岁儿童。
  • J301比较单剂JVC-001与对照疫苗(麻疹-风疹疫苗+腮腺炎疫苗[Hoshino株])的免疫原性。
  • J302为单剂低滴度或高滴度JVC-001的滴度确认研究。
  • 主要效力终点为第43天血清阳性率。
  • J301完成861人(JVC-001组n=429,对照组n=432);J302完成100人(低滴度组n=48,高滴度组n=52)。

主要发现

  • 麻疹和风疹病毒抗体滴度:JVC-001非劣效性成立,血清阳性率≥99.5%。
  • 腮腺炎病毒基因型D抗体滴度:JVC-001组血清阳性率80.6%(95%CI 76.5%至84.4%),对照组88.1%(95%CI 84.6%至91.0%),非劣效性未确认。
  • 低滴度组与高滴度组血清阳性率相似。
  • 两项研究均无导致停药的事件,也无无菌性脑膜炎病例。

关键数值与推荐

  • 麻疹和风疹血清阳性率JVC-001组≥99.5%,非劣效性成立。
  • 腮腺炎病毒基因型D血清阳性率JVC-001组80.6%(95%CI 76.5%至84.4%)vs 对照组88.1%(95%CI 84.6%至91.0%),非劣效性未确认。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: JVC-001 is a new live attenuated measles-mumps-rubella vaccine (measles AIK-C, mumps RIT4385, and rubella Takahashi strains). Two phase 3 studies were conducted, one to verify the non-inferior immunogenicity of JVC-001 versus the approved mumps and measles-rubella vaccines (J301 study) and another to compare the immunogenicity and safety of different titers (J302 study). METHODS: Both studies were multicenter, randomized, observer-blinded, phase 3 studies. J301 compared the immunogenicity elicited with a single dose of JVC-001 or control vaccines (measles-rubella vaccine + mumps vaccine [Hoshino strain]). J302 was a titer-confirmation study of a single dose of a low- or high-titer formulation of JVC-001. Both studies enrolled healthy Japanese children (aged 1 year) and had a primary efficacy endpoint of seropositive rate on Day 43. RESULTS: Overall, 861 participants completed J301 (JVC-001, n = 429; control, n = 432) and 100 participants completed J302 (low-titer, n = 48; high-titer, n = 52). For measles and rubella virus antibody titer, non-inferiority of JVC-001 was demonstrated: seropositive rates were ≥ 99.5 %. For mumps virus genotype D antibody titer, seropositive rates were 80.6 % (95 % confidence interval 76.5 % to 84.4 %) with JVC-001 and 88.1 % (84.6 % to 91.0 %) with control vaccination. Thus, non-inferiority for mumps virus genotype D antibody titer was not confirmed. Seropositive rates were similar in the low- and high-titer groups. There were no events leading to discontinuation, or cases of aseptic meningitis in either study. CONCLUSIONS: Although the non-inferiority of JVC-001 to currently approved vaccines was not demonstrated for the mumps component, clinical significance and consistent efficacy were indicated. Vaccine titer did not affect immunogenicity. JVC-001 is expected to have a lower risk of aseptic meningitis to currently approved vaccines and raised no new safety signals emerged.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nakayama T, Hamada S, Kawamura A, et al. Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children. Vaccine. 2025. PMID: 39920023. doi:10.1016/j.vaccine.2024.126698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。